KLHL14: A Novel Prognostic Biomarker and Therapeutic Target for Ovarian Cancer

Table 1

Baseline values of KLHL14 expression and clinical information.

Characteristic	Low expression of KLHL14	High expression of KLHL14
n	189	190
FIGO stage, n (%)			0.777
Stage I	0 (0%)	1 (0.3%)
Stage II	10 (2.7%)	13 (3.5%)
Stage III	147 (39.1%)	148 (39.4%)
Stage IV	30 (8%)	27 (7.2%)
Primary therapy outcome, n (%)			0.553
PD	10 (3.2%)	17 (5.5%)
SD	12 (3.9%)	10 (3.2%)
PR	22 (7.1%)	21 (6.8%)
CR	110 (35.7%)	106 (34.4%)
Race, n (%)			0.310
Asian	8 (2.2%)	4 (1.1%)
Black or African American	10 (2.7%)	15 (4.1%)
White	165 (45.2%)	163 (44.7%)
Age, years, median (IQR)	57 (49, 68)	60 (53, 68)	0.091